Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190405 | 0.94 | DRD3 (0.55) | DRD3MEN1MAPTKMT2ACYP2D6 | |
| SCHEMBL1802062 | 0.90 | DRD3 (0.59) | DRD3MEN1MAPTKMT2ACYP2D6 | |
| Hydrochloric Acid SCHEMBL2476701 | 0.89 | MAPK1 (0.60) | DRD3MEN1MAPTKMT2ACYP2D6 | |
| SCHEMBL12064967 | 0.87 | DRD3 (0.52) | DRD3MEN1MAPTKMT2ACYP2D6 | |
| SCHEMBL4189035 | 0.85 | TSHR (0.45) | DRD3MEN1MAPTKMT2ACYP2D6 | |
| SCHEMBL27978433 | 0.85 | SLC6A4 (0.48) | DRD3MEN1MAPTKMT2ACYP2D6 | |
| SCHEMBL14814326 | 0.84 | SLC6A2 (0.51) | DRD3CYP2D6CYP1A2TSHRDRD2 | |
| SCHEMBL9352969 | 0.84 | DRD3 (0.54) | DRD3MEN1MAPTKMT2ACYP2D6 | |
| SCHEMBL4179768 | 0.84 | DRD3 (0.53) | DRD3MEN1MAPTKMT2ACYP2D6 | |
| SCHEMBL4179765 | 0.84 | DRD3 (0.53) | DRD3MEN1MAPTKMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-2578569-B1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARM CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| EP-2578569-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| EP-0508334-B1 | Novel aminophenol derivatives and pharmaceutical compositions thereof | GREEN CROSS CORP (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-5308840-A | Antioxidants, antiallergens and antiinflammatory agents | GREEN CROSS CORPORATION (JP) | 1994-05-03 | — | — | US | disclosed |
| EP-0335586-B1 | PIPERIDINE & PIPERAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | UBE INDUSTRIES, LTD. (JP) | 1993-06-02 | — | — | EP | disclosed |
| EP-0529365-A1 | Diarylmethoxypiperidine derivatives | Kaken Pharmaceutical Co., Ltd. (JP) | 1993-03-03 | — | — | EP | disclosed |
| US-5190959-A | Antihistamines, antiallergens, treatment of ischemic heart disease | KAKEN PHARMACEUTICAL CO. LTD. (JP) | 1993-03-02 | — | — | US | disclosed |
| EP-0508334-A2 | Novel aminophenol derivatives and pharmaceutical compositions thereof | THE GREEN CROSS CORPORATION (JP) | 1992-10-14 | — | — | EP | disclosed |
| US-4929618-A | ANTIALLERGENS, ANTIHISTAMINES | UBE INDUSTRIES, LTD. (JP) | 1990-05-29 | — | — | US | disclosed |
| EP-0335586-A1 | Piperidine & piperazine derivatives, process for preparing the same and pharmaceutical compositions containing the same | UBE INDUSTRIES, LTD. (JP) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | HRH2, HRH4, HRH1 | DRD3 293/4885MEN1 2318/4885MAPT 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.